Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe

The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy.

Source: CancerNetwork - October 4, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news